表紙:癌治療薬市場 - 市場の洞察、競合情勢、市場予測:2027年
市場調査レポート
商品コード
1067710

癌治療薬市場 - 市場の洞察、競合情勢、市場予測:2027年

Oncology Drugs- Market Insights, Competitive Landscape and Market Forecast-2027

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 100 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=135.61円
癌治療薬市場 - 市場の洞察、競合情勢、市場予測:2027年
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 100 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の癌治療薬の市場規模は、2021年に1,799億6,000万米ドルとなりました。同市場は、2022年~2027年までの予測期間中に12.74%のCAGRで拡大し、2027年には3,682億2,000万米ドルに達すると予測されています。

当レポートでは、世界の癌治療薬市場について調査し、市場の概要とともに、治療タイプ別、癌タイプ別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 癌治療薬市場レポートのイントロダクション

第2章 癌治療薬市場のエグゼクティブサマリー

第3章 規制および特許分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 癌治療薬市場の主な要因分析

  • 癌治療薬市場の促進要因
    • さまざまな癌の発生率の上昇
    • 癌の発生に寄与する外的要因の増加
    • 精密医療と標的療法の人気の高まり
    • 製品開発における技術的進歩
  • 癌治療薬市場の抑制要因と課題
    • 癌治療に関連する潜在的な副作用
    • 癌治療薬の高コスト
  • 癌治療薬市場の機会

第5章 癌治療薬市場におけるポーターのファイブフォース分析

  • 売り手の交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係

第6章 COVID-19が癌治療薬市場に及ぼすの影響分析

第7章 癌治療薬市場のレイアウト

  • 治療タイプ別
    • 化学療法
    • ホルモン療法
    • 標的療法
    • その他
  • 癌タイプ別
    • 乳癌
    • 肺癌
    • 前立腺癌
    • 血液癌
  • エンドユーザー別
    • 病院
    • 専門クリニック
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 世界の癌治療薬市場の企業シェア分析-主要企業3~5社

第9章 癌治療薬市場の企業と製品プロファイル

  • GlaxoSmithKline
  • Eli Lilly & Company
  • F. Hoffmann-La Roche Ltd,
  • AbbVie Inc.
  • Amgen Inc.
  • Sanofi
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • AstraZeneca
  • Bristol Myers Squibbs
  • Gilead Sciences, Inc.
  • Janssen Global Services, LLC
  • BAYER AG
  • Celldex Therapeutics Inc
  • Alaunos Therapeutics, Inc.,
  • Astellas Pharma Inc
  • Genentech Inc
  • Sandoz International GmbH
  • BeiGene

第10章 KOL の見解

第11章 プロジェクトアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis on Oncology Drugs Market
  • Table 3: Oncology Drugs Market in Global (2019-2027)
  • Table 4: Oncology Drugs Market in Global by Therapy Type (2019-2027)
  • Table 5: Oncology Drugs Market in Global by Cancer Type (2019-2027)
  • Table 6: Oncology Drugs Market in Global by End User (2019-2027)
  • Table 7: Oncology Drugs Market in Global by Geography (2019-2027)
  • Table 8: Oncology Drugs Market in North America (2019-2027)
  • Table 9: Oncology Drugs Market in North America by Country (2019-2027)
  • Table 10: Oncology Drugs Market in the US (2019-2027)
  • Table 11: Oncology Drugs Market in Canada (2019-2027)
  • Table 12: Oncology Drugs Market in Mexico (2019-2027)
  • Table 13: Oncology Drugs Market in Europe (2019-2027)
  • Table 14: Oncology Drugs Market in Europe by Country (2019-2027)
  • Table 15: Oncology Drugs Market in France (2019-2027)
  • Table 16: Oncology Drugs Market in Germany (2019-2027)
  • Table 17: Oncology Drugs Market in the United Kingdom (2019-2027)
  • Table 18: Oncology Drugs Market in Italy (2019-2027)
  • Table 19: Oncology Drugs Market in Spain (2019-2027)
  • Table 20: Oncology Drugs Market in Russia (2019-2027)
  • Table 21: Oncology Drugs Market in Rest of Europe (2019-2027)
  • Table 22: Oncology Drugs Market in APAC (2019-2027)
  • Table 23: Oncology Drugs Market in APAC by Country (2019-2027)
  • Table 24: Oncology Drugs Market in China (2019-2027)
  • Table 25: Oncology Drugs Market in Japan (2019-2027)
  • Table 26: Oncology Drugs Market in India (2019-2027)
  • Table 27: Oncology Drugs Market in Australia (2019-2027)
  • Table 28: Oncology Drugs Market in South Korea (2019-2027)
  • Table 29: Oncology Drugs Market in Rest of APAC (2019-2027)
  • Table 30: Oncology Drugs Market in Rest of World (2019-2027)
  • Table 31: Oncology Drugs Market in RoW by Region (2019-2027)
  • Table 32: Oncology Drugs Market in Middle East (2019-2027)
  • Table 33: Oncology Drugs Market in Africa (2019-2027)
  • Table 34: Oncology Drugs Market in South America (2019-2027)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis on Oncology Drugs Market
  • Figure 3: Oncology Drugs Market in Global (2019-2027)
  • Figure 4: Oncology Drugs Market in Global by Therapy Type (2019-2027)
  • Figure 5: Oncology Drugs Market in Global by Cancer Type (2019-2027)
  • Figure 6: Oncology Drugs Market in Global by End User (2019-2027)
  • Figure 7: Oncology Drugs Market in Global by Geography (2019-2027)
  • Figure 8: Oncology Drugs Market in North America (2019-2027)
  • Figure 9: Oncology Drugs Market in North America by Country (2019-2027)
  • Figure 10: Oncology Drugs Market in the US (2019-2027)
  • Figure 11: Oncology Drugs Market in Canada (2019-2027)
  • Figure 12: Oncology Drugs Market in Mexico (2019-2027)
  • Figure 13: Oncology Drugs Market in Europe (2019-2027)
  • Figure 14: Oncology Drugs Market in Europe by Country (2019-2027)
  • Figure 15: Oncology Drugs Market in France (2019-2027)
  • Figure 16: Oncology Drugs Market in Germany (2019-2027)
  • Figure 17: Oncology Drugs Market in the United Kingdom (2019-2027)
  • Figure 18: Oncology Drugs Market in Italy (2019-2027)
  • Figure 19: Oncology Drugs Market in Spain (2019-2027)
  • Figure 20: Oncology Drugs Market in Russia (2019-2027)
  • Figure 21: Oncology Drugs Market in Rest of Europe (2019-2027)
  • Figure 22: Oncology Drugs Market in APAC (2019-2027)
  • Figure 23: Oncology Drugs Market in APAC by Country (2019-2027)
  • Figure 24: Oncology Drugs Market in China (2019-2027)
  • Figure 25: Oncology Drugs Market in Japan (2019-2027)
  • Figure 26: Oncology Drugs Market in India (2019-2027)
  • Figure 27: Oncology Drugs Market in Australia (2019-2027)
  • Figure 28: Oncology Drugs Market in South Korea (2019-2027)
  • Figure 29: Oncology Drugs Market in Rest of APAC (2019-2027)
  • Figure 30: Oncology Drugs Market in Rest of World (2019-2027)
  • Figure 31: Oncology Drugs Market in RoW by Region (2019-2027)
  • Figure 32: Oncology Drugs Market in Middle East (2019-2027)
  • Figure 33: Oncology Drugs Market in Africa (2019-2027)
  • Figure 34: Oncology Drugs Market in South America (2019-2027)
  • Figure 35: Market Drivers
  • Figure 36: Market Barriers
  • Figure 37: Marker Opportunities
  • Figure 38: PORTER'S Five Force Analysis
目次
Product Code: DIMDCL0518

Oncology Drugs Market By Therapy Type (Chemotherapy, Hormonal Therapy, Targeted Therapy [Gene Therapy And Immunotherapy], And Others), By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Blood Cancers, And Others), By End User (Hospitals, Specialty Clinics, And Others), and by geography is estimated to grow at a healthy CAGR forecast till 2026 due to rising prevalence of various cancers such as lung and breast cancers and growing demand for targeted therapies for cancer treatment

Global oncology drugs market was valued at USD 179.96 Billion in 2021, growing at a CAGR of 12.74% during the forecast period from 2022 to 2027, in order to reach USD 368.22 Billion by 2027. The oncology drugs market is witnessing a positive market growth owing to the factors such as rising prevalence of various cancers such as lung cancer which accounted for the highest number of cancer-related deaths and highest cancer incidence in 2021, and presence of factors such as growth in aging population wherein age plays a key role in cancer development in certain cancer types such as prostate and breast cancers. Moreover, the growing focus on developing targeted therapies such as CAR-T cell therapies to provide a more pronounced therapeutic effect is further driving the oncology drugs market as new products are gaining regulatory approvals for cancer treatment.

Oncology Drugs Market Dynamics:

One of the key aspects driving the oncology drugs market can be attributed to the surge in cancer incidence. The GLOBOCAN study conducted by the International Agency for Research on Cancer mentioned that in 2020, an estimated number of 19.3 million new cancer cases (18.1 million excluding non-melanoma skin cancer) and approximately 10.0 million cancer deaths were reported globally. The source mentioned above also stated that in 2020, lung cancer was the main cause accounting for the highest number (1.4 million) of cases followed by prostate (14.1%), colorectum (10.6%), stomach (7.1%), and liver (6.3%) cancers. Cancer, being a debilitating disease, requires extensive treatment in order to treat cancerous cells. Even though not all cancer would require treatment, most of them do. Various therapies such as chemotherapy, gene therapy, and immunotherapy are employed in cancer treatment due to the benefits associated with them in terms of providing curative as well as palliative effect in cancer treatment. Thus, the growing need for oncology drugs of various types can be attributed to the increasing cancer incidence which may respond to different therapy types. Therefore, all the aforementioned factors are projected to contribute to the growing demand for oncology drugs, ultimately boosting the growth of the global oncology drugs market.

Considering the increasing incidence of cancers, most of the pharmaceutical companies are focusing on extensive research and development activities in the oncology domain. This has resulted in more products being launched in the market. For instance, the US Food and Drug Administration (FDA) granted the regulatory approval for their supplemental new drug application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia. In another example, in May 2021, the US FDA approved Johnson & Johnson's infused therapy Rybrevant for the treatment of non-small cell lung cancer with a certain mutation to a cancer protein called epidermal growth factor.

However, potential side-effects associated with different cancer therapies such as loss of bone mass and cost of oncology drugs especially in low- and middle-income countries may prove to be challenging factors for oncology drugs market growth.

The oncology drugs market was negatively impacted by the implementation of measures to curb the spread of the COVID-19 infection. In order to cater to the exigency created by the COVID-19 pandemic, all other medical specialties witnessed a reduction in patient load. For instance, according to Cancer Research UK, in the UK alone, urgent lung cancer referrals fell up to 75% during the first lockdown. This did not correlate to the decrease in cases, but that fewer people sought and obtained the diagnosis they urgently needed. Unfortunately, these trends were prominent across countries around the globe. Nevertheless, the market for oncology drugs is on a period of recovery owing to devising of strategies to transform cancer care thereby presenting a future outlook for oncology drugs market during the forecast period from 2022-2027.

Oncology Drugs Market Segment Analysis:

Oncology Drugs Market by Therapy Type (Chemotherapy, Hormonal Therapy, Targeted Therapy [Gene Therapy and Immunotherapy], and Others), by Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Blood Cancers, and Others), by End User (Hospitals, Specialty Clinics, and Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the therapy type segment of the oncology drugs market, the targeted therapy category is estimated to account for a prominent revenue share in market during the forecast period (2022-2027). This can be attributed to the advantages associated with targeted therapy. Owing to its specificity in targeting proteins and genes of interest and providing better prognostic outcomes in terms of eliminating cancer cells, targeted therapy is being preferred as the choice of treatment in oncology. One of the key aspects associated with cancer cells is the ability to evade immune system checkpoints; targeted therapy helps in marking cancer cells enabling in their identification by the immune system thereby helping in their destruction.

Considering the advantages associated with targeted therapy, there are currently over 900 applications with the US Food and Drug Administration to investigate gene therapy in clinical trials. This has also resulted in an increased number of product approvals in the market. For instance, in March 2021, the US FDA approved the idecabtagene vicleucel (Abecma) for the treatment of multiple myeloma in patients with relapsed or treatment-resistant myeloma.

Thus, owing to the factors stated above, this therapy category is expected to witness a considerable growth eventually contributing the overall growth of the global oncology drugs market in the forecast period.

North America is expected to dominate the overall Oncology Drugs Market:

Among all the regions, North America is estimated to amass the largest revenue share in the global oncology drugs market. This can be ascribed to the high prevalence of cancers, and a supportive regulatory environment among other factors in the region. Furthermore, high disposable income, sophisticated healthcare infrastructure, and increased awareness regarding new treatments coupled with extensive insurance coverage for these treatments are also expected to aid in the oncology drugs market growth in this region.

One of the key supporting factors for the growth of the North America oncology drugs market is the increasing prevalence of cancers in the United States. As per the figures mentioned by the American Cancer Society, in 2021, it was estimated that 1.9 million new cancer cases would have been diagnosed in the United States. The data provided by the Centers for Disease Control and Prevention (2021), in 2018, 1,708,921 new cases of cancers were reported. For instance, the American Cancer Society estimates that in 2022, approximately 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the United States. Therefore, the increasing incidence of cancers such as breast cancer along with other cancer types in the country is expected to further drive the demand for oncology drugs thereby contributing in the growth of the United States oncology drugs market along with the overall growth of the North America oncology drugs market.

Furthermore, as the demand for targeted therapies in cancer treatment is witnessing an increase, there has been a major focus on extensive research and development in translation research leading to the development of new therapies as well as product approvals for the same. For instance, in September 2021, Health Canada approved LUMAKRAS™ (sotorasib) - the first and only targeted treatment for patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer. Similarly, in May 2020, the US Food and Drug Administration granted regulatory approval for the treatment of adult patients with non-small cell lung cancer (NSCLC) that has spread to other parts of the body.

Thus, such product development activities along with other contributing factors such as the presence of a robust healthcare system and insurance coverage are further driving the demand for oncology drugs in the North American region.

Oncology Drugs Market Key Players:

Some of the key market players operating in the oncology drugs market includes GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc., Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, BAYER AG., Celldex Therapeutics Inc., Alaunos Therapeutics, Inc., Astellas Pharma Inc., Genentech, Inc., Sandoz International GmbH, and BeiGene others.

Recent Developmental Activities in Oncology Drugs Market:

  • In October 15, 2021, the US FDA approved atezolizumab (Tecentriq) by Genentech, Inc. for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC).
  • In August 2021, Bristol Myers Squibbs received the conditional marketing authorization for Abecma (idecabtagene vicleucel) by the European Commission for the treatment of adult patients with relapsed and refractory multiple myeloma. It is a first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy.
  • In April 2021, Sanofi announced the acquisition of Tidal Therapeutics which is involved in the development of mRNA-based research platform. This acquisition will help Sanofi utilize this technology platform to expand their capabilities in the field of immunology and oncology.

Key Takeaways from the Oncology Drugs Market Report Study

  • Market size analysis for current oncology drugs market size (2021), and market forecast for 5 years (2022-2027)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the oncology drugs market.
  • Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
  • Key companies dominating the global oncology drugs market.
  • Various opportunities available for the other competitors in the oncology drugs market space.
  • What are the top performing segments in 2021? How these segments will perform in 2027.
  • Which is the top-performing regions and countries in the current oncology drugs market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for oncology drugs market growth in the coming future?

Target Audience who can be benefited from this Oncology Drugs Market Report Study

  • Oncology drugs products providers
  • Research organizations and consulting companies
  • Oncology drugs -related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in oncology drugs
  • Various End-users who want to know more about the oncology drugs market and latest technological developments in the oncology drugs market.

Frequently Asked Questions for Oncology Drugs Market:

1. What is Oncology Drugs?

  • Oncology drugs encompasses all kinds of cancer treatments such as chemotherapy, radiation therapy, hormonal therapy and targeted therapy among others that aim to kill cancer cells to provide therapeutic effect.

2. What is the global market for Oncology Drugs?

  • Global oncology drugs market was valued at USD 179.96 Billion in 2021, growing at a CAGR of 12.74% during the forecast period from 2022 to 2027, in order to reach USD 368.22 Billion by 2027.

3. What are the drivers for Global Oncology Drugs Market?

  • The oncology drugs market is witnessing a positive market growth owing to the factors such as rising prevalence of rising prevalence of cancers such as lung cancer which are contributing in the growing demand for cancer treatment, and presence of factors such as increasing aging population wherein age plays a key role in cancer development in certain cancer types such as breast cancer. Moreover, the growing focus on developing targeted therapies to provide a more pronounced therapeutic effect is further driving the oncology drugs market as new products are gaining regulatory approvals for cancer treatment.

4. Who are the key players operating in Global Oncology Drugs Market?

  • Some of the key market players operating in the oncology drugs market includes GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, BAYER AG., Celldex Therapeutics Inc., Alaunos Therapeutics, Inc., Astellas Pharma Inc., Genentech, Inc., Sandoz International GmbH, and BeiGene others.

5. Which region has the highest share in Oncology Drugs Market?

  • North America is expected to hold the highest share in the revenue in the Oncology Drugs market during the forecast period. This can be ascribed to the high prevalence of cancers, and a supportive regulatory environment among other factors in the region. Furthermore, high disposable income, sophisticated healthcare infrastructure, and increased awareness regarding new treatments coupled with extensive insurance coverage for these treatments are also expected to aid in the oncology drugs market growth in this region.

Table of Contents

1.Oncology Drugs Market Report Introduction

2.Oncology Drugs Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment
  • 2.4. Financial Benchmarking

3. Regulatory and Patent Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Oncology Drugs Market Key Factors Analysis

  • 4.1. Oncology Drugs Market Drivers
    • 4.1.1. Increasing Incidence of Various Cancers
    • 4.1.2. Rise in External Factors Contributing in Cancer Development
    • 4.1.3. Growing Popularity of Precision Medicine and Targeted Therapy
    • 4.1.4. Technological Advancements in Product Development
  • 4.2. Oncology Drugs Market Restraints and Challenges
    • 4.2.1. Potential Side-Effects Associated with Cancer Therapies
    • 4.2.2. High Cost of Oncology Drugs
  • 4.3. Oncology Drugs Market Opportunities
    • 4.3.1. Improving Affordability of Cancer Therapies
    • 4.3.2. Development of Safer Cancer Therapies with Minimal Side-Effects

5. Oncology Drugs Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Oncology Drugs Market

7. Oncology Drugs Market Layout

  • 7.1. By Therapy Type
    • 7.1.1. Chemotherapy
    • 7.1.2. Hormonal Therapy
    • 7.1.3. Targeted Therapy
      • 7.1.3.1. Gene Therapy
      • 7.1.3.2. Immunotherapy
    • 7.1.4. Others
  • 7.2. By Cancer Type
    • 7.2.1. Breast Cancer
    • 7.2.2. Lung Cancer
    • 7.2.3. Prostate Cancer
    • 7.2.4. Blood Cancers
    • 7.2.5. Others
  • 7.3. By End User
    • 7.3.1. Hospitals
    • 7.3.2. Specialty Clinics
    • 7.3.3. Others
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. North America Oncology Drugs Market, by Country
      • 7.4.1.4.1. United States
      • 7.4.1.4.2. Canada
      • 7.4.1.4.3. Mexico
    • 7.4.2. Europe
      • 7.4.2.1. Europe Oncology Drugs Market, by Country
      • 7.4.2.4.1. France
      • 7.4.2.4.2. Germany
      • 7.4.2.4.3. United Kingdom
      • 7.4.2.4.4. Italy
      • 7.4.2.4.5. Spain
      • 7.4.2.2.6. Russia
      • 7.4.2.2.7. Rest of Europe
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. Asia-Pacific Oncology Drugs Market, by Country
      • 7.4.3.4.1. China
      • 7.4.3.4.2. Japan
      • 7.4.3.4.3. India
      • 7.4.3.4.4. Australia
      • 7.4.3.4.5. South Korea
      • 7.4.3.4.6. Rest of Asia Pacific
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. RoW Oncology Drugs Market, by Region
      • 7.4.4.4.1. Middle East
      • 7.4.4.4.2. Africa
      • 7.4.4.4.3. South America

8. Oncology Drugs Market Global Company Share Analysis - Key 3-5 Companies

9. Oncology Drugs Market Company and Product Profiles

  • 9.1. GlaxoSmithKline
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4. Product Listing
    • 9.1.5. Entropy
  • 9.2. Eli Lilly & Company
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4. Product Listing
    • 9.2.5. Entropy
  • 9.3. F. Hoffmann-La Roche Ltd,
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4. Product Listing
    • 9.3.5. Entropy
  • 9.4. AbbVie Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4. Product Listing
    • 9.4.5. Entropy
  • 9.5. Amgen Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4. Product Listing
    • 9.5.5. Entropy
  • 9.6. Sanofi
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4. Product Listing
    • 9.6.5. Entropy
  • 9.7. Merck & Co., Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4. Product Listing
    • 9.7.5. Entropy
  • 9.8. Novartis AG
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4. Product Listing
    • 9.8.5. Entropy
  • 9.9. Pfizer Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4. Product Listing
    • 9.9.5. Entropy
  • 9.10. AstraZeneca
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4 Product Listing
    • 9.10.5. Entropy
  • 9.11. Bristol Myers Squibbs
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4. Product Listing
    • 9.11.5. Entropy
  • 9.12. Gilead Sciences, Inc.
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4. Product Listing
    • 9.12.5. Entropy
  • 9.13. Janssen Global Services, LLC
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4. Product Listing
    • 9.13.5. Entropy
  • 9.14. BAYER AG
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4. Product Listing
    • 9.14.5. Entropy
  • 9.15. Celldex Therapeutics Inc
    • 9.15.1. Company Overview
    • 9.15.2. Company Snapshot
    • 9.15.3. Financial Overview
    • 9.15.4. Product Listing
    • 9.15.5. Entropy
  • 9.16. Alaunos Therapeutics, Inc.,
    • 9.16.1. Company Overview
    • 9.16.2. Company Snapshot
    • 9.16.3. Financial Overview
    • 9.16.4. Product Listing
    • 9.16.5. Entropy
  • 9.17. Astellas Pharma Inc
    • 9.17.1. Company Overview
    • 9.17.2. Company Snapshot
    • 9.17.3. Financial Overview
    • 9.17.4. Product Listing
    • 9.17.5. Entropy
  • 9.18. Genentech Inc
    • 9.18.1. Company Overview
    • 9.18.2. Company Snapshot
    • 9.18.3. Financial Overview
    • 9.18.4. Product Listing
    • 9.18.5. Entropy
  • 9.19. Sandoz International GmbH
    • 9.19.1. Company Overview
    • 9.19.2. Company Snapshot
    • 9.19.3. Financial Overview
    • 9.19.4. Product Listing
    • 9.19.5. Entropy
  • 9.20. BeiGene
    • 9.20.1. Company Overview
    • 9.20.2. Company Snapshot
    • 9.20.3. Financial Overview
    • 9.20.4. Product Listing
    • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us